线粒体代谢重编程与NRF2/KEAP1-介导的抗氧化机制一起,驱动着质母细胞瘤多形体中的特莫佐洛米德抗性
Manendra Singh Tomar1, Chirag Kulkarni2,3,4, Kaveri R Washimkar5,3,4
1Center for Advance Research, Faculty of Medicine, King George's Medical University, Lucknow-226003, Uttar Pradesh India.
Journal of proteome research
|December 5, 2025
概括
质母细胞细胞通过改变其新陈代谢来对特莫佐洛米德 (TMZ) 治疗产生抗性. 由NRF2驱动的增强的线粒体活性和抗氧化防御,有助于这种耐药性.
科学领域:
- 在瘤学瘤学.
- 癌症新陈代谢 癌症新陈代谢
- 分子生物学分子生物学
背景情况:
- 泰莫佐洛米德 (TMZ) 是用于多种质母细胞瘤 (GBM) 的标准化疗.
- 获得的TMZ耐药性显著限制了大约一半的GBM患者的治疗疗效.
- 了解TMZ抗性的机制对于开发有效的治疗策略至关重要.
研究的目的:
- 研究细胞生物能学和新陈代谢在GBM中获得的TMZ耐药性的作用.
- 确定导致TMZ耐药性的关键代谢变化和分子途径.
主要方法:
- 利用非向的代谢学来分析耐TMZ的GBM细胞的代谢概况.
- 评估线粒体功能,包括质量和膜潜力.
- 关键蛋白质和代谢物的量化水平,包括NRF2,KEAP1,谷氨和酶.
主要成果:
- 耐TMZ的GBM细胞表现出显著的代谢重新连接,包括糖解,TCA循环和氨基酸代谢的改变.
- 线粒体活动,质量和膜潜力的增加与药物耐药性的增强相关.
- 较高的谷氨胺水平支持线粒体能量生产的增加.
- 提高NRF2/KEAP1通路的调节会导致抗氧化剂水平的增加 (谷氨,甲酶),减轻氧化应激,并促进耐药性.
结论:
- 线粒体代谢重编程和NRF2/KEAP1介导的抗氧化防御是GBM中获得TMZ耐药性的关键机制.
- 针对这些代谢和抗氧化途径,提出了一个潜在的新策略,以克服TMZ抵抗在质母细胞瘤治疗中.
相关概念视频
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
02:53Adaptive Mechanisms in Cancer Cells
6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K
01:46Electron Transport Chain: Complex I and II
18.4K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
18.4K
03:03mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
01:22PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K